By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Cannabis NewsCannabis News
Aa
  • Cannabis
  • CBD
  • Science
  • Culture & Arts
  • Cannabis Press Releases
  • More
    • About Maryjanes Post
    • Cannabis Advertising
    • Cannabis Partnerships
Reading: Rapid Dose Therapeutics and McMaster University’s COVID-19 Vaccine Study Receives NSERC Research and Development Grant
Share
Aa
Cannabis NewsCannabis News
Search
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • About Maryjanes Post
    • Ambassador
    • Cannabis Partnerships
Follow US
  • Ad Choices
  • RSS Terms of Service
© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.
Cannabis News > Cannabis Press Releases > Rapid Dose Therapeutics and McMaster University’s COVID-19 Vaccine Study Receives NSERC Research and Development Grant
Cannabis Press Releases

Rapid Dose Therapeutics and McMaster University’s COVID-19 Vaccine Study Receives NSERC Research and Development Grant

Business Wire
Business Wire December 22, 2021
Updated 2022/05/30 at 7:51 AM
Share
SHARE

BURLINGTON, Ontario–(BUSINESS WIRE)–$DOSE–Today, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) and McMaster University (“McMaster”) are pleased to announce that the ongoing development of an orally delivered vaccine candidate for COVID-19 has received the final installment of the Collaborative Research and Development grant, with a value of $120,000, from the Natural Sciences and Engineering Research Council of Canada (NSERC).

RDT LOGO Cannabis Media & PR

“We appreciate the ongoing support received from the Canadian government through NSERC as we continue to drive this important research forward,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “Global experts have called for a needle-free method of delivering vaccines for COVID-19 and many other diseases, and this research is paramount to supporting the commercialization of such an innovation.”

McMaster University research team lead Dr. Alex Adronov, PhD adds, “This installment allows us to continue our efforts in creating oral thin-film therapeutics for a variety of applications, including incorporation of vaccine components for needle-free vaccination.”

- Advertisement -

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 at this time.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

www.rapid-dose.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contacts

For more information:

Investor:
Mark Upsdell, CEO

[email protected]
416-477-1052

Media:
Kim Robinson

[email protected]
905-330-4055

You Might Also Like

Proposed Settlement Reached in 2016 Class Action

Akanda Announces Changes to Board of Directors and Postponement of Annual General Meeting

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

IIPR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Innovative Industrial Properties, Inc. and Encourages Investors to Contact the Firm

Creators of Muscle Milk Launch New Hemp Infused Sports Nutrition Brand GYM WEED in U.S. Market

TAGGED: Business Wire
Business Wire December 22, 2021
Share this Article
Twitter Reddit Email Copy Link
Previous Article High Tide Recaps Milestones of 2021
Next Article Organigram Makes Additional $2.5 Million Investment in Hyasynth Biologicals, a Leading Cannabinoid Biosynthesis Company

You Might Also Like

Proposed Settlement Reached in 2016 Class Action

June 24, 2022

Akanda Announces Changes to Board of Directors and Postponement of Annual General Meeting

June 24, 2022

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

June 23, 2022

IIPR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Innovative Industrial Properties, Inc. and Encourages Investors to Contact the Firm

June 23, 2022

Cannabis News and More

Work with an experienced cannabis media firm to provide your brand with the exposure it needs.

Cannabis Topics

  • Cannabis
  • Business
  • CBD
  • Cannabis Science
  • Culture & Arts

Company

  • About Maryjanes Post
  • Contact Cannabis Media
  • Contributor Guidelines

Terms of Use

  • TERMS
  • PRIVACY
  • CONTRIBUTOR AGREEMENT
  • DMCA

Resources

  • Write For UsNew
  • Cannabis Advertising
  • Cannabis Partnerships
  • Cannabis Press ReleaseNew
Cannabis NewsCannabis News
Follow US

© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.

Go to mobile version
Welcome Back!

Sign in to your account

Lost your password?